Latest Market Challenges News

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.

ALS Limited reported a 16% revenue increase to nearly $3 billion in FY2025, driven by acquisitions and organic growth, while underlying net profit after tax dipped slightly. The company announced a $350 million equity raise to fund expansion and sustainability initiatives.

Metro Performance Glass reported a net loss for FY25 amid market softness but outlines a clear recovery plan with leadership changes and an equity raise to strengthen its position.

Yowie Group has posted its first profitable seasonal quarter, driven by strategic cost control and product improvements, but faces ongoing capital challenges due to a significant loan default by Keybridge Capital.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

Sietel Limited’s half-year results to March 2025 reveal an 11% revenue drop and a near 50% plunge in net profit, reflecting tough market conditions in property leasing and startup investments.

Australis Oil & Gas reported a robust 2024 performance with strong safety and environmental records, maintaining strategic focus on its Tuscaloosa Marine Shale asset despite challenging market conditions.

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

Australian Agricultural Company Limited (AACo) reported a robust FY25 operating profit of $58.4 million, driven by increased meat and cattle sales volumes and strategic brand growth despite inflationary pressures.

Oceania Healthcare reported a 4.1% rise in underlying EBITDA for FY25, driven by strong sales and operational improvements, while launching a new strategic plan focused on growth and efficiency.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.